The goal of The Rockefeller University Center for Clinical and Translational Science is to improve human health by: 1. providing an infrastructure to conduct clinical investigation at the highest level, educational programs to train future generations of skilled and committed investigators, and novel methods of clinical investigation that can be shared with others, and 2. working closely with other CTSA institutions to set national standards so as to improve the conduct of Clinical research. The 2006 Clinical and Translational Science Award transformed translational research at Rockefeller University and we propose to build on these accomplishments by: 1) enhancing our KL2 Master's degree and Certificate in Clinical and Translational Science educational programs;2) creating a new educational program for our current K08 and K23 awardees to speed their transition to scientific independence;3) expanding our bidirectional community engaged research with our partner institutions, integrating molecular mechanistic and population-based components, 4) completing the implementation of our integrated, customized information technology infrastructure to facilitate protocol development, review, and conduct;5) implementing a novel real-time monitoring system to insure compliance with Good Clinical Practice;6) enhancing our multi-disciplinary and multi-departmental Protocol Navigation program to speed protocol development, approval, and implementation, and extending it to bidirectional community enaged research;7) expanding the application of novel nonparametric biostatistical methods to genomic and community-based investigation;8) utilizing our new deep human phenotyping systems to aid scientific discovery and address important clinical needs;9) utilizing a validated measure of research participants'perceptions to improve the conduct of clinical research;and 10) continuing to actively participate in the national CTSA consortium to advance the discipline of clinical and translational science for the benefit of human health.
; The Rockefeller University Center for Clinical and Translational Science is dedicated to improving human health by providing the resources and personnel to conduct the highest quality research to improve the prevention, diagnosis, and treatment of human disease. It also is producing novel methods to improve the scientific information obtained from clincial research studies and the way in which the research is performed.
|Gristick, Harry B; von Boehmer, Lotta; West Jr, Anthony P et al. (2016) Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol 23:906-915|
|Wang, Taia T; Ravetch, Jeffrey V (2015) Immune complexes: not just an innocent bystander in chronic viral infection. Immunity 42:213-5|
|Anandasabapathy, N; Breton, G; Hurley, A et al. (2015) Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant 50:924-30|
|Roberts, Wendy K; BlachÃ¨re, Nathalie E; Frank, Mayu O et al. (2015) A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. Ann Neurol 78:619-29|
|Dosenovic, Pia; von Boehmer, Lotta; Escolano, Amelia et al. (2015) Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell 161:1505-15|
|Anandasabapathy, Niroshana; Feder, Rachel; Mollah, Shamim et al. (2014) Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med 211:1875-91|
|BlachÃ¨re, Nathalie E; Orange, Dana E; Santomasso, Bianca D et al. (2014) TÂ cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol 44:3240-51|
|Mollah, Shamim A; Dobrin, Joseph S; Feder, Rachel E et al. (2014) Flt3L dependence helps define an uncharacterized subset of murine cutaneous dendritic cells. J Invest Dermatol 134:1265-75|
|Frank, Mayu O; Kaufman, Julia; Parveen, Salina et al. (2014) Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med 12:338|
|Orange, Dana E; Blachere, Nathalie E; Fak, John et al. (2013) Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo. Elife 2:e00105|
Showing the most recent 10 out of 13 publications